Literature DB >> 16423061

Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells.

Jason R Lees1, Bridget Charbonneau, Axel K Swanson, Robert Jensen, Jianfeng Zhang, Robert Matusik, Timothy L Ratliff.   

Abstract

Previous reports have demonstrated clonal deletion of CD8(+) T cells during peripheral tolerance induction to tissue antigens. However, direct evidence demonstrating a causal connection between deletion and tolerance has not been reported because of model limitations in which the tissue antigens were expressed in vital organs. Thus, studies were initiated in a mouse model where expression of a membrane-bound ovalbumin fusion protein (mOVA) was driven by a prostate specific androgen regulated probasin promotor, providing restricted expression in a non-vital organ where antigen levels can be abrogated through androgen deprivation. Adoptive transfer of mOVA specific CD8(+) T cells (OT-I) was used to assess the development of peripheral tolerance. Proliferation of OT-I cells was observed, as was partial deletion of transferred OT-I cells. Although deletion occurred, the long-term persistence of a stable level of OT-I cells was observed. Importantly, the persistent OT-I cells lost antigen responsiveness within 3 weeks of transfer. Castration resulted in loss of high-level prostate mOVA expression, with a resultant abrogation of tolerance induction, but surprisingly did not affect the deletion rate of OT-I cells. In contrast, abrogation of deletion through the adoptive transfer of OT-I cells from third generation CD95-deficient mice had no effect on tolerance induction. These data demonstrate the necessity for continued expression of tissue antigen throughout the establishment of peripheral tolerance. Furthermore, these findings demonstrate that deletion is neither sufficient nor required for CD8(+) T-cell tolerance to tissue antigens, suggesting that regulatory events independent of deletion are necessary for peripheral tolerance induction to prostate antigens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423061      PMCID: PMC1782220          DOI: 10.1111/j.1365-2567.2005.02293.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

1.  Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens.

Authors:  D J Morgan; H T Kreuwel; L A Sherman
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

2.  Expression of intestine-specific antigen reveals novel pathways of CD8 T cell tolerance induction.

Authors:  V Vezys; S Olson; L Lefrançois
Journal:  Immunity       Date:  2000-05       Impact factor: 31.745

3.  A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo.

Authors:  J Zhang; T Z Thomas; S Kasper; R J Matusik
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

4.  Altered functional and biochemical response by CD8+ T cells that remain after tolerance.

Authors:  A Murtaza; C T Nugent; P Tailor; V C Asensio; J A Biggs; I L Campbell; L A Sherman
Journal:  Int Immunol       Date:  2001-08       Impact factor: 4.823

5.  CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose.

Authors:  C Kurts; R M Sutherland; G Davey; M Li; A M Lew; E Blanas; F R Carbone; J F Miller; W R Heath
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix.

Authors:  D R Siemens; B D Elzey; D M Lubaroff; C Bohlken; R J Jensen; A K Swanson; T L Ratliff
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

7.  Persistence of physiological self antigen is required for the regulation of self tolerance.

Authors:  K M Garza; S S Agersborg; E Baker; K S Tung
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

8.  Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen.

Authors:  J Hernandez; S Aung; W L Redmond; L A Sherman
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

9.  Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.

Authors:  M V Dhodapkar; R M Steinman; J Krasovsky; C Munz; N Bhardwaj
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

10.  Role of antigen-presenting cells in mediating tolerance and autoimmunity.

Authors:  K M Garza; S M Chan; R Suri; L T Nguyen; B Odermatt; S P Schoenberger; P S Ohashi
Journal:  J Exp Med       Date:  2000-06-05       Impact factor: 14.307

View more
  14 in total

1.  An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate.

Authors:  Jessica M Haverkamp; Bridget Charbonneau; Scott A Crist; David K Meyerholz; Michael B Cohen; Paul W Snyder; Robert U Svensson; Michael D Henry; Hsing-Hui Wang; Timothy L Ratliff
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

2.  Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.

Authors:  Stefanie N Linch; Melissa J Kasiewicz; Michael J McNamara; Ian F Hilgart-Martiszus; Mohammad Farhad; William L Redmond
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

3.  Urinary bladder epithelium antigen induces CD8+ T cell tolerance, activation, and autoimmune response.

Authors:  Wujiang Liu; David P Evanoff; Xiaohong Chen; Yi Luo
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

4.  Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Authors:  William L Redmond; Stefanie N Linch; Melissa J Kasiewicz
Journal:  Cancer Immunol Res       Date:  2013-11-11       Impact factor: 11.151

5.  Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.

Authors:  Amy E Moran; Fanny Polesso; Andrew D Weinberg
Journal:  J Immunol       Date:  2016-08-08       Impact factor: 5.422

6.  Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells.

Authors:  Derese Getnet; Charles H Maris; Edward L Hipkiss; Joseph F Grosso; Timothy J Harris; Hung-Rong Yen; Tullia C Bruno; Satoshi Wada; Adam Adler; Robert W Georgantas; Chunfa Jie; Monica V Goldberg; Drew M Pardoll; Charles G Drake
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

7.  Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.

Authors:  William L Redmond; Michael J Gough; Andrew D Weinberg
Journal:  Eur J Immunol       Date:  2009-08       Impact factor: 5.532

8.  Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.

Authors:  Ailin Bai; Eileen Higham; Herman N Eisen; K Dane Wittrup; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-22       Impact factor: 11.205

Review 9.  T cell tolerance to the skin: a central role for central tolerance.

Authors:  Prisca Schuler; Emmanuel Contassot; Bertrand Huard
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 11.759

10.  Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.

Authors:  William L Redmond; Todd Triplett; Kevin Floyd; Andrew D Weinberg
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.